Novo Nordisk Middle Africa

Programmes and partnerships

In low- and middle-income countries, many people living with diabetes struggle to get the care they need. These challenges range from having medicine in stock at the pharmacy to a lack of trained doctors and nurses who can effectively diagnose and treat diabetes.

We know from experience that changing diabetes care for the better takes programmes and partnerships - no one organisation can solve the challenge alone.

For more than two decades, we've been partnering to bring solutions that help people access the diabetes care they need, no matter where they live. 


The Base of the Pyramid Project

Providing comprehensive care for people with diabetes

In 2010, Novo Nordisk established the Base of the Pyramid project to identify innovative and sustainable solutions that support an integrated approach to diagnosis, treatment and control of diabetes for people living at the base of the economic pyramid.

The project is implemented in Ghana, Kenya, Nigeria, Senegal and more recently, Morocco.

Base of Pyramid Programme Countries

Integrated diabetes care approach

  • Awareness & screening
  • Strengthened physical infrastructure
  • Training of healthcare professionals
  • Stable & affordable insulin supply
  • Patient education & self-management

Shared value for all partners

In all countries, the BoP project implements an integrated approach to ensure comprehensive diabetes care for people.

The programs are established as public-private partnerships that promote shared responsibility between Novo Nordisk, governments and local health authorities, in alignment with the United Nations Sustainable Development Goals (SDGs).

Action across components of integrated care

Ghana, Kenya, Nigeria & Senegal only

Strengthened Physical Infrastructure

  • 6 Centers of Excellence
  • 16 Diabetes Support Centers
  • 360 Faith-based facilities

 Training of Healthcare Professionals

  •  >6,000 Healthcare professionals trained

Stable & Affordable Insulin Supply

  • Improve accessibility and affordability of insulin to end-user 

Changing Diabetes® in Children

No child should die from diabetes

Children living with type 1 diabetes in low-income countries are one of the most vulnerable populations who often face the greatest risk associated with inadequate access to insulin and medical care.

In Novo Nordisk, we believe no child should die from diabetes and to address these critical unmet needs, we established the Changing Diabetes® in Children program in 2009. The program is implemented in 14 countries, 10 of which are in Africa.

cdic  Country Project Overview

Sustainable partnerships for change

The Changing Diabetes® in Children program is a public-private partnership program between Novo Nordisk, Roche, the International Society for Paediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF). In each country, the program is implemented by a group of local partners and national ministries of health. 


2020 ambition & results

The Changing Diabetes® in Children program uses a holistic approach to improve access to quality care and treatment for children living with type 1 diabetes. The program focuses on six areas that address local challenges to ensure impact:

  • Improvement of existing infrastructure
  • Training and education of healthcare professionals
  • Provision of human insulin and blood glucose monitoring equipment
  • Patient education including diabetes camps
  • Advocacy and good practice sharing
  • Patient registry system


Progress at the end of 2019:

Progress form 2019

The current ambition is to reach 20,000 children by 2020. By the end of 2019, the program has reached more than 25,000 children and adolescents living with type 1 diabetes. 


Access to Insulin Commitment

Novo Nordisk introduced a differential pricing policy to increase low-priced human insulin for least developed countries (LDCs) in 2001, many of which are in Middle Africa countries. In 2019, the scope was updated to include the Access to Insulin Commitment to lower the ceiling price and include humanitarian relief settings.

In addition to the ceiling price for LDCs, Novo Nordisk is committed to working with others to improve the efficiency of supply chains and government procurement and tendering.

For more information visit  the access to Insulin commitment page

We are driving change to defeat diabetes and we continue to innovate and invest in sustainable approaches that address gaps in access to care.

For more information, please contact: Abigail Chakava, Public Affairs & Projects Manager, Novo Nordisk, Middle Africa,, +254-798-471-705.